Company intelligence / Profile preview

Wake Network

Ownership: Private
Development stage: Phase 2

Overview

Received approval for Phase 2b psilocybin microdosing clinical trial with the University of the West Indies. Successfully completed the first legal importation of psilocybin mushrooms into the United States with DEA approval. Developed PSIL428 microdose drug that has been federally registered and approved.

Therapeutic areas: PsychiatryNeurology
Modalities: Psilocybin mushroomsFungi-based therapeuticsMedicinal mushroom products
Industry: Biotech

Drug pipeline

1 asset

PSIL428

Unknown

Partnerships

Revitalist Lifestyle and Wellness Ltd.Lieber InstituteUniversity of the West Indies

Beyond the preview

Go deeper on Wake Network.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Wake Network.

Explore the full profile